The FDA decision on Coherus BioSciences Inc.’s (CHRS) Toripalimab is expected on December 23, 2022.Toripalimab, a PD-1 inhibitor, in combination with gemcitabine and cisplatin, is proposed as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and as monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.This is the company’s second attempt to get FDA approval for Toripalimab. In May of this year, the U.S. regulatory agency had declined to approve Toripalimab, requesting a quality process change. Toripalimab is developed by Shanghai Junshi Bioscience Co., Ltd. Coherus in-licensed rights to develop and commercialize Toripalimab in the United States and Canada from Junshi in January 2021.In China, Toripalimab is approved for 6 indications including metastatic melanoma, metastatic urothelial carcinoma, metastatic nasopharyngeal carcinoma and metastatic, nonsquamous non–small cell lung cancer not harboring EGFR mutations or ALK fusions, among others, and is marketed there as Tuoyi.CHRS closed Friday’s trading at $6.58, up 0.46%.